Onpattro®

Understanding Onpattro® 

Onpattro® (patisiran) is a small interfering RNA (siRNA) therapy used to treat polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. It works by targeting and silencing specific genetic instructionsresponsible for the production of abnormal transthyretin (TTR) protein. By reducing TTR protein buildup, Onpattro® helps prevent amyloid deposits from accumulating in the nerves, which can improve neurological function and enhance quality of life for affected patients.

How Onpattro® Works:

• Silences TTR gene expression, reducing amyloid deposits in the body.
• Prevents nerve damage, improving neurological function.
• Helps manage symptoms, enhancing patient quality of life.

FDA Approval:

• Onpattro® (patisiran): Approved in August 2018 for the treatment of polyneuropathy in hATTR amyloidosis.

For more information, please visit the Onpattro® patient website and speak with your healthcare provider to determine if Onpattro® is the right treatment option for you.